title: A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.
abstract: BACKGROUND
  Acid suppression plus two antibiotics is considered the reference anti-Helicobacter pylori treatment. Reported eradication rates are around 65-80%. Human Lactobacillus acidophilus shows an in vitro inhibitory effect on the attachment of H. pylori to gastric epithelial cell lines. Culture supernatant of this bacillus seems to decrease the in vitro viability of H. pylori.
  
  
  OBJECTIVE
  To evaluate whether the supplementation with an inactivated preparation of L. acidophilus could improve the efficacy of a standard anti-H. pylori therapy.
  
  
  METHODS
  One-hundred and twenty H. pylori-positive patients were randomly assigned to a 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.) and amoxicillin (500 mg t.d.s.) (RCA group: 60 subjects), or to the same regimen supplemented with a lyophilized and inactivated culture of Lactobacillus acidophilus (t.d.s.) (RCAL group: 60 subjects).
  
  
  RESULTS
  In the RCA group, eradication was successful in 72% (42 out of 58 patients) from a per protocol (PP) analysis, or 70% (42 out of 60 patients) using an intention-to treat (ITT) analysis. In the RCAL group a significant increase in the eradication rate was observed: 88% (52 out of 59 patients) from PP analysis (P=0.03), 87% (52 out of 60 patients) from ITT analysis (P=0.02).
  
  
  CONCLUSIONS
  These results seem to confirm the in vitro anti-H. pylori effect of L. acidophilus, suggesting that the inactivated L. acidophilus could be effective in increasing eradication rates of a standard anti-H. pylori therapy.
authors: Department of Internal Medicine, Catholic University of Rome, Italy.
authors: F
authors: F
authors: Canducci
authors: A
authors: A
authors: Armuzzi
authors: F
authors: F
authors: Cremonini
authors: G
authors: G
authors: Cammarota
authors: F
authors: F
authors: Bartolozzi
authors: P
authors: P
authors: Pola
authors: G
authors: G
authors: Gasbarrini
authors: A
authors: A
authors: Gasbarrini
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007779:Lactobacillus acidophilus / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D010349:Patient Compliance; D011446:Prospective Studies; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole